When someone with liver cirrhosis starts bleeding from swollen veins in their esophagus, it's a race against time. Doctors use a drug called terlipressin to help stop the bleeding, but there's been a question about the best way to give it: as a quick injection or as a slow, steady drip into the vein. A fresh look at the evidence from six past trials, involving 494 patients, suggests the slow drip might be the better choice. The analysis found that the continuous infusion was linked to significantly less treatment failure and less rebleeding. It also came with fewer overall side effects, and the researchers noted that higher doses seemed tied to more heart-related issues. For a different but related complication where the kidneys start to fail, both methods worked about the same. It's important to note that while there was a trend toward fewer deaths with the continuous drip for the bleeding patients, that finding wasn't strong enough to be sure. This analysis pulls together the best data we have so far, pointing doctors toward what could be a safer and more effective standard practice for a life-threatening situation.
Continuous terlipressin infusion reduces treatment failure and rebleeding in acute variceal bleedingCould a different way of giving a bleeding drug save more lives?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider continuous terlipressin infusion for AEVB based on meta-analysis showing reduced treatment failure and rebleeding.
This meta-analysis of 6 randomized controlled trials included 494 patients with cirrhosis, comparing continuous versus bolus terlipressin infusion for acute esophageal variceal bleeding (AEVB) and hepatorenal syndrome (HRS). For AEVB, continuous infusion significantly reduced treatment failure (relative risk 0.32; 95% CI 0.12-0.87; p=0.03) and rebleeding (RR 0.52; 95% CI 0.33-0.81; p<0.01). Mortality showed a non-significant trend favoring continuous infusion (RR 0.62; 95% CI 0.30-1.28; p=0.19). For HRS, response rates were comparable between groups (RR 1.11; 95% CI 0.87-1.41; p=0.40).
Safety analysis found continuous infusion reduced total adverse events (RR 0.59; 95% CI 0.45-0.76; p<0.01), with a noted correlation between drug dose and cardiovascular adverse events. Serious adverse events, discontinuation rates, and tolerability details were not reported. The analysis used random-effects models and performed subgroup analyses, but did not report primary outcome definitions, follow-up duration, or funding/conflict disclosures.
Key limitations include the modest total sample size (494 patients across 6 trials), unreported primary outcome, and lack of individual patient data. The mortality finding remains a non-significant trend requiring cautious interpretation. For clinical practice, continuous terlipressin infusion appears associated with reduced treatment failure, rebleeding, and adverse events in AEVB, while maintaining comparable efficacy in HRS. However, these findings derive from a meta-analysis of limited RCTs and should inform rather than dictate practice until larger confirmatory studies are available.
What this means for you:
A slow drip of a key drug may work better and be safer for stopping dangerous bleeding in cirrhosis. More on Cirrhosis
Observational study links semaglutide dose and weight loss to lower liver disease risk
Study links semaglutide use to lower risk of several liver conditions in patients with liver disease
This observational study from a real-world federated EHR network analyzed 6,734 patients with liver disease.
Higher semaglutide doses and greater weight loss were linked to lower risks of steatohepatitis, alcoholic liver disease, and death in patien…
Machine learning models show moderate to high accuracy for predicting variceal bleeding in cirrhosis patients
New AI Tool Catches Bleeding Risks Early
A systematic review and meta-analysis of 21 studies involving 7,011 cirrhosis patients found machine learning models achieved pooled c-indic…
An AI tool now spots bleeding risks in liver disease earlier than current methods, helping doctors catch dangerous vein swelling before it t…
Endovascular interventions reduce rebleeding risk versus endoscopic cyanoacrylate injection in gastric variceal hemorrhage
Endovascular procedures reduce rebleeding risk for cirrhosis patients compared to injection therapy
This individual patient data meta-analysis compares endovascular interventions with endoscopic cyanoacrylate injection for gastric variceal …
A meta-analysis of 1,240 patients found endovascular procedures significantly lower rebleeding rates than injection therapy, though they car…
Antimicrobial resistance reaches 33.3% in cirrhosis patients with bacterial infections across global settings
Antimicrobial resistance is rising in cirrhosis patients worldwide
This systematic review and meta-analysis examines bacterial infections in 35,180 adult patients with cirrhosis globally. The analysis report…
A global analysis of 35,180 patients with cirrhosis shows rising antimicrobial resistance and varying mortality risks.
View Original Abstract ↓
BACKGROUND & AIMS: Terlipressin is crucial for treating acute oesophageal variceal bleeding (AEVB) and hepatorenal syndrome (HRS). This meta-analysis compared the continuous versus bolus terlipressin infusion for treating the above conditions in patients with cirrhosis.
METHODS: Three major databases were searched for randomised controlled trials (RCTs) comparing two infusion strategies. A meta-analysis was conducted to estimate the risk ratios (RR) with a 95% confidence interval (CI) based on a random-effects model. Subgroup analyses were performed to account for adverse events (AEs) in terms of severity and organ systems. Additionally, a dose-response analysis was conducted to evaluate the correlation between drug dosage and AEs.
RESULT: Six RCTs (494 patients) were included. Compared with bolus infusion, continuous terlipressin infusion showed less treatment failure (RR, 0.32; 95% CI, 0.12-0.87; p = 0.03), less rebleeding (RR, 0.52; 95% CI, 0.33-0.81; p < 0.01) and a trend toward lower mortality (RR, 0.62; 95% CI, 0.30-1.28; p = 0.19) in patients with AEVB, while response rates were comparable in patients with HRS (RR, 1.11; 95% CI, 0.87-1.41; p = 0.40) and a risk reduction of total AEs (RR, 0.59; 95% CI, 0.45-0.76; p < 0.01). Subgroup analyses stratifying AEs supported these findings, and a correlation was noted between drug dose and cardiovascular AEs.
CONCLUSION: Compared to bolus administration, continuous terlipressin infusion reduces treatment failure and rebleeding rates in patients with AEVB; provides a comparable response rate in patients with HRS; and decreases the incidence of total, severe, and cardiovascular AEs while allowing for lower overall doses.
Higher TyG Index Linked to 4.36-Fold Increased Odds of NAFLD in Large Meta-Analysis
TyG Index Linked to Higher Fatty Liver Risk
Related in Gastroenterology
Acupuncture modulates the microbiota-gut-brain axis to remodel microbial structure in patients with irritable bowel syndrome
Acupuncture May Help Manage Irritable Bowel Syndrome Symptoms
This systematic review examines how acupuncture influences the microbiota-gut-brain axis in patients with irritable bowel syndrome. The auth…
New research suggests acupuncture may help manage irritable bowel syndrome by improving gut bacteria and balancing the gut-brain connection.
Reduced Shannon index indicates lower alpha-diversity in the gut microbiota of patients with primary biliary cholangitis
Gut Microbiota Differences Linked to Primary Biliary Cholangitis
This meta-analysis of 1,057 participants found that patients with primary biliary cholangitis have significantly lower Shannon index values …
A large review of patient data shows that people with primary biliary cholangitis have significantly lower gut bacterial diversity than heal…
Probiotic supplementation may improve salivary buffering and reduce cariogenic bacteria
A review of six studies shows probiotics may help oral and gut health in people
This systematic review of 6 reviews suggests probiotic supplementation may improve salivary buffering capacity and plaque pH, reduce Strepto…
This review looked at six studies on probiotic supplements. Results suggest better saliva function and fewer bad mouth bacteria, though stud…
Balloon-assisted ESD shows comparable outcomes to conventional ESD for colorectal polyps
Balloon-assisted endoscopic submucosal dissection shows shorter procedure time in RCTs
This systematic review and meta-analysis of 1449 patients found that balloon-assisted endoscopic submucosal dissection (BA-ESD) and conventi…
A meta-analysis of 1,449 patients found balloon-assisted endoscopic submucosal dissection had shorter procedure times in randomized trials, …
From Other Specialties
Fibromyalgia as an oncology comorbidity increases symptom burden and impairs treatment adherence
Fibromyalgia makes managing cancer pain more difficult for patients
This systematic review of 11 studies examines fibromyalgia as a comorbidity in cancer patients. The findings indicate that fibromyalgia cont…
Patients with both fibromyalgia and cancer face higher symptom burdens and may stop life-saving treatments sooner due to intense, amplified …
Physical exam algorithm distinguishes benign anal masses, guides surgical decisions
New Clinical Algorithm Helps Identify Anal Masses and Prolapse
This narrative review proposes a clinical decision algorithm based on physical examination to differentiate benign lesions prolapsing throug…
Doctors can now use a specific physical examination guide to tell the difference between rectal prolapse, hemorrhoids, and other anal condit…
Individualized six-phase antithrombotic strategy leads to left ventricular thrombus resolution and neurological recovery
New strategy helps manage heart blood clots after heart attack
This case report describes an individualized six-phase antithrombotic strategy for a 27-year-old male with myocardial infarction, stroke, hy…
A tailored six-phase treatment plan helped a young man recover fully from a stroke and heart attack while successfully clearing dangerous bl…
Heterogeneous definitions and clinical inconsistencies currently hinder the accurate identification of treatment-resistant depression
New ways to define treatment resistant depression are emerging
This narrative review examines the phenotypic definition of treatment-resistant depression (TRD) and its associated biological correlates. T…
Doctors struggle to treat some types of depression because the current definition is inconsistent. New research looks at how biology and beh…